Effect of anionic surfactants on antiviral efficacy

Abstract

Virucidal compositions and methods of using the same are provided. [Solution] Virucidal compositions are provided that include at least one acid and an alpha olefin sulfonate anionic surfactant. In particular, they provide virucidal efficacy against murine norovirus at improved rates over comparable anionic surfactants. Methods of using the virucidal compositions are also provided.

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority under Section 119 of the United States Patent Act to U.S. Provisional Application No. 62 / 948,378, filed on 16 December 2019, which is incorporated herein by reference in its entirety. The entirety of this patent application, including, without limitation, the specification, claims, and abstract, and any figures, tables, or drawings thereof, is expressly incorporated herein by reference.

[0002] The present invention relates to a virucidal composition comprising an alpha-olefin sulfonate anionic surfactant and at least one acid. In particular, the virucidal composition provides a composition effective for bactericidal action against murine norovirus, having an acceptable working solution pH that does not require the use of personal protective equipment (PPE), being surface-compatible, and not leaving streaky, cloudy, or sticky residues on the treated surface. The composition provides an effective alternative to quaternary ammonium compounds. Methods for using the virucidal composition are also provided. [Background technology]

[0003] Viral pathogens are a growing public health concern. Pathogenic viruses pose a significant health concern because they can persist on surfaces for extended periods and require complete and reliable inactivation to halt disease transmission. Viruses can be identified according to a hierarchy corresponding to their level of resistance to inactivation. Three virus subgroups include small non-enveloped viruses, large non-enveloped viruses, and enveloped viruses. A virucidal product capable of inactivating small non-enveloped viruses can also inactivate any large non-enveloped virus or any enveloped virus. Similarly, a virucidal product capable of inactivating large non-enveloped viruses can also inactivate any enveloped virus. Therefore, it is desirable to identify and develop compositions capable of inactivating small non-enveloped viruses, and then having corresponding efficacy across the viral hierarchy. Norovirus is an exemplary small non-enveloped virus that requires an additional virucidal composition for surface treatment.

[0004] Norovirus is an exemplary small, non-enveloped virus that requires additional antimicrobial compositions for surface treatment. Formerly known as "Norwalk-like virus" (NLV) or small spherical virus, non-enveloped norovirus (NoV) is the most important viral pathogen of epidemic acute gastroenteritis occurring in both developed and developing countries. NoV belongs to the Calciviridae family and is an icosahedral single-stranded positive-sense RNA virus whose capsid consists of 180 copies of a single major structural protein. Norovirus is the leading cause of gastroenteritis in the United States, with an estimated 23 million cases of acute gastroenteritis annually in the US alone. Of all viruses, only the common cold is reported more frequently than viral gastroenteritis (norovirus). Norovirus causes nausea, vomiting (sometimes accompanied by diarrhea), and stomach cramps. The infection is usually spread from person to person through direct contact.

[0005] Norovirus is highly contagious and spreads easily from person to person. People can become infected with norovirus in several ways, such as by eating or drinking food or liquids contaminated with norovirus, touching a surface or object contaminated with norovirus and then putting their hands in their mouth, or by having direct contact with another person who is infected and showing symptoms (e.g., caring for a sick person or sharing food or utensils with a sick person). Several modes of transmission have been recorded when norovirus gastroenteritis develops, for example, initial foodborne transmission in restaurants followed by secondary person-to-person transmission through household contact.

[0006] Methods for culturing human norovirus in cell cultures are not widely available and are limited. As a result, studies evaluating methods for inactivating norovirus often utilize surrogate viruses, including feline calicivirus (FCV) in cats, murine norovirus (MNV) in mice, porcine enteric calicivirus (PEC) in pigs, and Tulane virus (TuV) in rhesus monkeys. FCV has been cultured for decades and has become a classic substitute for norovirus.

[0007] It is well known in the art that different norovirus surrogates have different resistances to different inactivation methods. FCV is recognized as one of the most susceptible to various inactivation methods, including low pH. MNV is recognized as acid-resistant. Acid-resistant surrogates best represent enteric viruses (such as human norovirus) because they can survive the acidic pH of the stomach and reach target cells in the small intestine for infectivity. Additionally, compared to FCV, MNV is genetically closer to human norovirus. With that in mind, acid-resistant norovirus surrogates such as MNV, which are more genetically related to human norovirus, are more suitable surrogates than FCV for studying the environmental survival of human norovirus.

[0008] Quaternary ammonium compounds have become common antimicrobial agents and are widely used in the food service industry as food contact disinfectants and sterilizers with disinfection claim sets requiring follow-up rinsing. However, recent regulatory scrutiny of quaternary ammonium compounds may change the use of these disinfectant and sterilizer compositions.

[0009] Products with a no-rinse function are desirable, but these present challenges because all active and inactive ingredients have designated list tolerances for chemicals used as components in antimicrobial disinfectants applied to food contact surfaces in public eating and drinking places, dairy processing equipment, and food processing equipment and cookware. A variety of commercially available products offering norovirus no-rinse options exist on the market, including, for example, Purell Professional Food Service Sanitizer disclosed in U.S. Patent No. 8,143,309, and Pure Bioscience Pure Hard Surface disclosed in U.S. Patents No. 6,197,814 and No. 6,583,176, the entirety of which is incorporated by reference. A further commercial example is the EU product Sarafan Speed, an alcohol-based no-rinse antiviral product. However, various challenges are presented by these products. For example, various products present flammability concerns, impart poor surface appearance with cloudy and / or sticky residues and / or limited compatibility with soft metal surfaces (including aluminum), and are only available as ready-to-use (RTU) formulations instead of concentrates and / or solids, which limits the applications of these uses. As a result, there are various limitations in establishing a demand for improved compositions. [Overview of the project] [Problems that the invention aims to solve]

[0010] Therefore, the object of the composition and method is to provide a product that can provide sterilization without rinsing. In such embodiments, the rinsing step can be excluded from the method. Similarly, in such embodiments, the wiping step can be further excluded from the method. A further object of the composition and method is to provide a product that provides sterilization without the use of quaternary ammonium compounds.

[0011] A further object of the composition and method is to provide virucidal effectiveness against murine norovirus in addition to other viruses (enveloped and non-enveloped viruses), and to ensure proper sterilization against human norovirus.

[0012] An even further object of the composition and method is to provide virucidal effectiveness including a short contact time, preferably 60 minutes or less, more preferably 30 minutes or less, more preferably 10 minutes or less, even more preferably 5 minutes or less, and most preferably 1 minute or less. In some embodiments, the short contact time is achieved under clean conditions. In other embodiments, the short contact time is achieved under contaminated or soiled conditions.

[0013] A further object of the composition and method is a treatment option having a use solution pH that does not require the use of personal protective equipment (PPE).

[0014] An even further object of the composition and method is to provide a synergistic combination of an alpha olefin sulfonate anionic surfactant and at least one acid, and the acid can be a strong acid, a weak acid, or a combination thereof.

[0015] An even further object is to provide both solid and liquid compositions.

[0016] Other objects, advantages, and features of the present invention will become apparent from the following specification in conjunction with the accompanying drawings.

Means for Solving the Problems

[0017] The advantages of the virucidal composition include providing a surface-compatible formulation that functions with short contact times, including less than 60 minutes, less than 30 minutes, less than 10 minutes, less than 5 minutes, less than 1 minute, less than approximately 30 seconds, or even less than approximately 15 seconds, while also providing a dilutable, non-flammable, bactericidal compositional efficacy against microbial pathogens, including viruses such as murine norovirus. Since regulatory requirements in jurisdictions vary depending on the contact time required for efficacy against viral pathogens, it is beneficial for the virucidal composition to be surface-compatible over longer contact times of at least 60 minutes, while still being effective within seconds (e.g., less than approximately 15 seconds). A further advantage of compositions and methods using solution pH is that users do not need to use PPE. Furthermore, the composition is suitable for use as a hard surface antimicrobial composition, i.e., a virucidal composition as an alternative to quaternary ammonium compounds.

[0018] In one embodiment, the antimicrobial composition comprises at least one acid, wherein the acid is a strong acid, a weak acid, and / or a combination thereof; at least one alpha-olefin sulfonate anionic surfactant; and water for a liquid composition, wherein the composition is a liquid or solid concentrate having an acidic pH of about 1.5 to about 4 in the composition of use.

[0019] In further embodiments, the alpha-olefin sulfonate is a C8-C22 alpha-olefin sulfonate or a C8-C16 alpha-olefin sulfonate. In further embodiments, the acid includes lactic acid and methanesulfonic acid. In further embodiments, the acid is a single or combination of weak acids combined with the alpha-olefin sulfonate surfactant. In even further embodiments, the acid is a single or combination of strong acids combined with the alpha-olefin sulfonate surfactant. In further embodiments, the composition also includes an alkoxylated nonionic surfactant having an EO / PO block copolymer.

[0020] In further embodiments, a method using a virucidal composition comprises contacting the virucidal composition with a surface to be treated and inactivating a viral population, wherein the antiviral inactivation is completed by reducing at least three times to n within about 60 minutes, about 30 minutes, about 5 minutes, about 1 minute, about 30 seconds, or even less than about 15 seconds, and the method optionally does not require a rinsing step. In embodiments, contact is by wiping, dipping, immersion, or spraying, and the surface is a hard surface, a pre-cleaned hard surface, and / or a dirty surface contaminated with a viral population.

[0021] Although several embodiments are disclosed, other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description illustrating and describing illustrative embodiments of the present invention. Therefore, the drawings and embodiments for carrying out the invention should be considered as illustrative and not limiting in nature. [Brief explanation of the drawing]

[0022] [Figure 1] This specification demonstrates the bactericidal efficacy of various anionic chemicals analyzed herein, compared to negative (non-anionic) controls and positive LAS controls. [Figure 2] The results of the antiviral effectiveness of various anionic chemicals against adenoviruses were presented, and antiviral effectiveness requires the killing of more than four logarithmic adenoviruses within 15 minutes. [Figure 3] The results of the antiviral effectiveness of various anionic chemicals against MNVs were presented, and antiviral effectiveness requires the killing of more than four logarithms within 15 minutes. [Figure 4] This paper presents the antiviral efficacy results of various anionic chemicals against MNVs at dilutions of less than 1% and shorter contact times, which are tested for 4-logarithmic or greater elimination, necessary for antiviral effectiveness.

[0023] Various embodiments of the present invention will be described in detail with reference to the drawings, where similar reference numerals in some figures represent similar parts. References to various embodiments do not limit the scope of the present invention. The figures shown herein are not limited to various embodiments of the present invention, but are presented for illustrative purposes. [Modes for carrying out the invention]

[0024] The present invention relates to liquid and solid antimicrobial compositions that provide efficacy against microorganisms and viral pathogens while offering surface-compatible formulations that do not leave cloudy, streaky, or sticky residues on the treated surface and do not require PPE. In some embodiments, the compositions provide no-rinse efficacy against viral pathogens, including MNVs. Embodiments are not limited to specific compositions and their methods of use, and are modifiable and will be understood by those skilled in the art. Furthermore, it should be understood that all technical terms used herein are intended solely to describe specific embodiments and are not intended to limit them in any form or scope. For example, as used herein and in the appended claims, the singular forms "a," "an," and "the" may include plural referents unless the content clearly indicates otherwise. Furthermore, all units, prefixes, and symbols may be shown in their SI-recognized form.

[0025] Numerical ranges enumerated herein include numbers within a defined range. Throughout this disclosure, various aspects of the invention are presented in range form. It should be understood that descriptions in range form are for convenience and conciseness only and should not be construed as inflexible limitations on the scope of the invention. Accordingly, descriptions of ranges should be considered to specifically disclose all possible subranges and individual numbers within that range (for example, 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).

[0026] To facilitate understanding of the present invention, certain terms are first defined. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to whom embodiments of the present invention relate. Many methods and materials similar, modified, or equivalent to those described herein can be used in carrying out embodiments of the present invention without excessive experimentation, and preferred materials and methods are described herein. In describing and claiming embodiments of the present invention, the following technical terms are used according to the definitions set forth below.

[0027] When used herein, the term "approximately" refers to variations in quantity that may arise, for example, from common measurement and liquid handling procedures used in the real world to prepare concentrates or solutions, from careless errors in these procedures, from differences in the manufacture, source, or purity of components used to prepare a composition or carry out a method. The term "approximately" also encompasses different quantities resulting from different equilibrium conditions for compositions arising from a particular initial mixture. Whether modified by the term "approximately" or not, the claims include equivalent quantities.

[0028] The terms “active substance,” “percentage of active substance,” “weight percentage of active substance,” or “active substance concentration” are used interchangeably herein and refer to the concentration of a component involved in purification, expressed as a percentage after subtracting inert components such as water or salt.

[0029] As used herein, the terms “alkyl” or “alkyl group” refer to saturated hydrocarbons having one or more carbon atoms, and include linear alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.), cycloalkyl groups (or “cycloalkyl,” “alicyclic,” or “carbocyclic” groups) (e.g., cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc.), branched alkyl groups (e.g., isopropyl, tert-butyl, sec-butyl, isobutyl, etc.), and alkyl-substituted alkyl groups (e.g., alkyl-substituted cycloalkyl groups and cycloalkyl-substituted alkyl groups).

[0030] Unless otherwise specified, the term “alkyl” includes both “unsubstituted alkyl” and “substituted alkyl.” As used herein, the term “substituted alkyl” refers to an alkyl group having substituents that substitute one or more hydrogens of one or more carbons in a hydrocarbon skeleton. Such substituents include, for example, alkenyl, alkynyl, halogeno, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonate, phosphinato, shea Possible examples include amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido), imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamide, nitro, trifluoromethyl, cyano, azide, heterocyclic, alkylaryl, or aromatic (including heteroaromatic) groups.

[0031] In some embodiments, the substituted alkyl group may include a heterocyclic group. As used herein, the term “heterocyclic group” includes a ring-closed structure similar to a carbocyclic group in which one or more carbon atoms in the ring are elements other than carbon, such as nitrogen, sulfur, or oxygen. The heterocyclic group may be saturated or unsaturated. Examples of heterocyclic groups include, but are not limited to, aziridine, ethylene oxide (epoxide, oxirane), thiirane (episulfide), dioxirane, azetidine, oxetane, thiethane, dioxetane, dithiethane, dithiethone, azolidine, pyrrolidine, pyrroline, oxolane, dihydrofuran, and furan.

[0032] The distinction between antimicrobial "killing" and "bacteriostatic" activity, definitions explaining the degree of effectiveness, and formal laboratory protocols for measuring this effectiveness are considerations for understanding the relevance of antimicrobial agents and compositions. Antimicrobial compositions can affect two types of microbial cell damage. The first is lethal and irreversible action, resulting in the complete destruction or incapacitation of microbial cells. The second type of cell damage is reversible, and therefore, once the organism is released from its agent, it can grow again. The former is called bactericidal, and the latter bacteriostatic. Sanitizers and disinfectants are, by definition, agents that provide antimicrobial or bactericidal activity. In contrast, preservatives are generally described as inhibitors or bacteriostatic compositions. As referred to herein, antimicrobial compositions are more preferably bactericidal in activity against viral pathogens, including norovirus and murine norovirus, for example, including the use of EN14476 at 18°C ​​to 25°C (under clean or contaminated conditions).

[0033] As used herein, the term “cleaning” refers to methods used to facilitate or assist in the removal of dirt, bleaching, reduction of microbial populations, rinsing, and any combination thereof.

[0034] As used herein, the term “microorganism” refers to any noncellular or single-celled (including colonies) organism. Microorganisms include all prokaryotes. Microorganisms include bacteria (including cyanobacteria), spores, lichens, fungi, protists, virinos, viroids, viruses, phages, and some algae. As used herein, the term “microbe” is synonymous with “microorganism.”

[0035] The term “commercially acceptable cleaning performance” generally refers to the degree of cleanliness, effort, or both that a typical consumer can expect to achieve or consume when using a cleaning product or cleaning system to address a typical soiling condition on a typical substrate. This degree of cleanliness may, depending on the particular cleaning product and substrate, correspond to a general absence of visible soiling or a somewhat lower degree of cleanliness. Cleanliness may be assessed in various ways depending on the particular product used and the particular surface being cleaned, and is usually determined using generally agreed industry standard tests or localized variations of such tests. In some embodiments, a method that provides virucidal efficacy also provides commercially acceptable cleaning performance while ensuring that the formulation does not leave a cloudy, streaky, or sticky residue on the treated surface.

[0036] As used herein, the term “fungicide” refers to a drug that kills all vegetative cells, including the most commonly recognized pathogenic microorganisms. In one embodiment, a fungicide according to U.S. standards may be the AOC Use Dilution Methods, Official Methods of Analysis of the Association of Official Analytical Chemists, paragraph 955.14 and applicable sections, 15th Edition, 1990 (EPA Guideline 91-2). As used herein, the term “high-level fungicide” or “high-level fungicide” refers to a compound or composition influenced by a chemical fungicide that kills substantially all organisms except high levels of bacterial spores and is authorized by the Food and Drug Administration to be marketed as a sterilizer. As used herein, the term “intermediate-level fungicide” or “intermediate-level fungicide” refers to a compound or composition that kills mycobacteria, most viruses, and bacteria using a chemical pathogen registered by the Environmental Protection Agency (EPA) as a tuberculosis fungicide. As used herein, the terms “low-level disinfectant” or “low-level fungicide” refer to compounds or compositions that kill certain viruses and bacteria using chemical pathogens registered by the EPA as hospital disinfectants.

[0037] In one embodiment, a fungicide in accordance with EU standards is as described in Directive 98 / 8 / EC of the European Parliament and Council of 16 February 1998, and Guidance on the Biocidal Products Regulation Volume II Efficacy-Assessment and Evaluation (Parts B+C) Version 3.0 April 2018 - ECHA (European Chemicals Agency), each of which is incorporated herein by reference in whole.

[0038] The fungicide may include any one of four groups of biocidal products having five defined product types for products that reduce the number of microorganisms in or on an inanimate matrix, achieved by the irreversible action of the product. In one embodiment, the fungicide product can be verified using various recognized test methods (CEN, OECD, ISO, etc.); see Guidebook Appendices 2 and 4. According to various embodiments of the methods and compositions described herein, fungicide performance at a 5-log reduction requirement was demonstrated using the EN1276 methodology, and fungicide performance at a 4-log reduction requirement was demonstrated using the EN14476 methodology.

[0039] As used herein, the term “food processing surface” refers to the surface of tools, machinery, equipment, structures, buildings, etc., used as part of food processing, cooking, or preservation activities. Examples of food processing surfaces include the surfaces of food processing or cooking equipment (e.g., slicing equipment, canning equipment, or transport equipment, including water channels), food processing supplies (e.g., the surfaces of kitchen utensils, dishes, washing supplies, and bar glasses, and the surfaces of floors, walls, or fixtures of structures where food processing takes place). Food processing surfaces are found and used in food spoilage prevention air circulation systems, aseptic packaging disinfection, cleaners and disinfectants for food refrigeration and coolers, supplies cleaning and disinfection, blancher cleaning and disinfection, food packaging materials, cutting board additives, third-sink disinfection, beverage coolers and warmers, water for meat cooling or hot water treatment, automatic dish disinfectants, disinfectant gels, cooling towers, antimicrobial clothing sprays for food processing, and non-aqueous to low-aqueous food processing lubricants, oils, and rinsing additives.

[0040] The term "hard surface" refers to solid, substantially inflexible surfaces such as countertops, tiles, floors, walls, panels, windows, sanitary fixtures, kitchen and bathroom fittings, electrical appliances, engines, circuit boards, and dishes. Hard surfaces may also include, for example, healthcare surfaces and food processing surfaces.

[0041] As used herein, the term “healthcare surface” refers to the surface of instruments, devices, carts, cages, furniture, structures, buildings, etc., used as part of healthcare activities. Examples of healthcare surfaces include the surfaces of medical fabrics or dental instruments, medical devices or dental devices, the surfaces of electronic devices used to monitor patient health, and the surfaces of floors, walls, or fixtures of structures in which healthcare takes place. Medical surfaces are found in hospitals, surgical facilities, frailty centers, maternity homes, funeral homes, and clinical diagnostic rooms. These surfaces may be represented as “hard surfaces” (e.g., walls, floors, bedpans), or woven surfaces, such as knitted, woven, and nonwoven surfaces (e.g., surgical clothing, curtains, bed linens, bandages), or patient care equipment (e.g., respiratory equipment, diagnostic equipment, shunts, body scopes, wheelchairs, beds), or surgical and diagnostic equipment. Medical surfaces also include articles and surfaces used in veterinary medicine.

[0042] The term "improved cleaning performance" generally refers to the degree of cleanliness achieved by an alternative cleaning product or system, when using an alternative cleaning product or system instead of a conventional cleaning product to address typical soiling conditions on a typical substrate, with generally higher cleanliness, generally reduced effort, or both. Depending on the specific cleaning product and substrate, this level of cleanliness may correspond to the complete absence of visible dirt and a treated surface free from cloudy, streaky, or sticky residues.

[0043] When used in reference to a list of materials, the terms “contains” and “contains” refer to, but are not limited to, the materials listed in that way.

[0044] As used herein, the term “instrument” refers to any medical or dental instrument or device that may benefit from the cleaning / viral treatment described herein.

[0045] As used herein, the term “viridid ​​agent” refers to an agent that reduces the number of viruses on a surface or substrate. In one embodiment, a virucidal composition will provide a reduction of at least three-logarithmic order, preferably five-logarithmic order, or more preferably complete inactivation of the virus. These reductions can be evaluated using the procedure described in ASTM E1053 Standard Test Method for Efficacy of Virucidal Agents Intended for Inanimate Environmental Surfaces, the US standard is described in EPA810.2200, and the EP standard is described in EN14476, each of which is incorporated herein by reference in whole. The logarithmic reductions outlined can be achieved over a variety of times (which may vary according to contact time requirements described in different jurisdictions), including, for example, less than about 60 minutes, less than about 30 minutes, less than about 5 minutes, less than 1 minute, less than about 30 seconds, or even less than about 15 seconds. According to this reference, a virucidal composition must provide a 99.9% reduction in virucidal activity (a reduction of three-logarithmic order).

[0046] As used herein, the term “virus” refers to a type of microorganism that may include both pathogenic and non-pathogenic viruses. Pathogenic viruses can be classified into two general types in terms of viral structure: enveloped viruses and non-enveloped viruses. Well-known enveloped viruses include herpesviruses, influenza viruses; paramyxoviruses, respiratory syncytial viruses, coronaviruses, HIV, hepatitis B virus, hepatitis C virus, and SARS-CoV virus. Non-enveloped viruses, sometimes called “naked” viruses, include those belonging to the Picornaviridae, Reoviridae, Caliciviridae, Adenoviridae, and Parvoviridae families. Members of these families include rhinoviruses, polioviruses, adenoviruses, hepatitis A virus, noroviruses, papillomaviruses, and rotaviruses. In the art, “enveloped” viruses are known to be relatively susceptible and therefore can be inactivated by commonly used disinfectants. In contrast, non-enveloped viruses are substantially more resistant to conventional fungicides and are far more environmentally stable than enveloped viruses.

[0047] The term "norovirus" is intended to refer to human norovirus (simply called norovirus), which belongs to the Caliciviridae family and is the primary cause of acute nonbacterial gastroenteritis. To date, there are various surrogates commonly used for norovirus, and human norovirus cannot be grown in cell culture. Norovirus has a low infectious dose (10-100 virus particles), and environmental contamination prolongs outbreaks. Surfaces, dishes or containers, cooking utensils, and food handled by sick individuals who have not practiced proper personal hygiene before preparing food can also contribute to the illness. Feline calicivirus (FCV), from the Vesivirus genus, can be grown in cell culture and is widely studied as a surrogate of human norovirus in environmental survival and inactivation studies. However, FCV is transmitted via the respiratory route and is inactivated at relatively low pH, and therefore may not predict the environmental stability or inactivation of human norovirus. Muline norovirus 1 (MNV-1) has been grown in cell cultures and causes lethal infections in mice that manifest as hepatitis, pneumonia, or inflammation of the nervous system, and thus the clinical symptoms are very different from those of human norovirus. MNV-1 is excreted in mouse feces and is generally transmitted via the fecal-oral route. The genetic relationship between MNV-1 and norovirus, combined with its ability to survive at gastric pH levels (minimal decrease in infectivity at pH 2), makes this virus a suitable surrogate for studying the environmental survival of norovirus. MNV-1 can survive low pH and is more acid-tolerant compared to FCV.

[0048] As used herein, the term “disinfectant” refers to an agent that reduces the number of bacterial contaminants to a safe level, as determined by public health requirements. In one embodiment, the disinfectant used in the present invention will provide a reduction of at least 3-logarithmic order, more preferably on the order of 5-logarithmic order. These reductions can be evaluated using the procedures described in Germicidal and Detergent Sanitizing Action of Disinfectants, Official Methods of Analysis of the Association of Official Analytical Chemists, paragraphs 960.09 and applicable parts, 15th Edition, 1990 (EPA Guideline 91-2). According to this reference, the disinfectant should provide a 99.999% reduction (a reduction on the order of 5-logarithmic order) to several test organisms within 30 seconds at room temperature, 25±2°C.

[0049] As used herein, the term “dirt” refers to polar or nonpolar organic or inorganic substances, including but not limited to carbohydrates, proteins, fats, and oils. These substances may exist in their organic state or may form inorganic complexes with metals.

[0050] As used herein, the term “substantially absent” means a composition that either completely lacks the component or contains such a small amount of the component that it does not affect the performance of the composition. The component may be present as an impurity or contaminant and must be less than 0.5% by weight. In another embodiment, the amount of the component is less than 0.1% by weight, and in yet another embodiment, the amount of the component is less than 0.01% by weight.

[0051] The term "threshold agent" refers to a compound that inhibits the crystallization of hard water ions originating from a solution, but does not require the formation of a specific complex with those hard water ions. Examples of threshold agents, though not limited to these, include polyacrylates, polymethacrylates, and olefin / maleic acid copolymers.

[0052] As used herein, the term “water” includes various water sources. Water temperatures may range from approximately 40°F to 160°F, approximately 60°F to 140°F, or approximately 70°F to 140°F.

[0053] The term "water-soluble" refers to a compound that can dissolve in water at a concentration greater than 1% by weight. The term "slowly soluble" or "slightly water-soluble" refers to a compound that can dissolve in water only up to a concentration of 0.1 to 1.0% by weight. The term "water-insoluble" refers to a compound that can dissolve in water only up to a concentration of less than 0.1% by weight.

[0054] The terms "weight percent," "wt-%," "percent by weight," "% by weight," and their variations, as used herein, refer to the concentration of a substance obtained by dividing its weight by the total weight of the composition and multiplying by 100. As used herein, "percent," "%," etc., are intended to be synonymous with "weight percent," "wt-%," etc.

[0055] The methods and compositions of the present invention, like other components described herein, may include, be essentially derived from, or consist of the components and components of the present invention. As used herein, “essentially derived from” means that the methods and compositions may include further steps, components, or components, provided that the further steps, components, or components do not substantially alter the basic and novel features of the claimed methods and compositions.

[0056] As used herein and in the appended claims, the term “configured” should be noted to describe a system, apparatus, or other structure that is built or configured to perform a particular task or to conform to a particular form. The term “configured” may be used interchangeably with other similar phrases such as arranged and configured, built and arranged, adapted and configured, and adapted, built, manufactured and arranged.

[0057] Virucidal composition Exemplary ranges of antiviral compositions are shown in Tables 1A-1C, representing liquid concentrate formulations on a weight percentage basis, and in Table 2, representing solid formulations on a weight percentage basis. [Table 1A] [Table 1B] [Table 1C] [Table 2]

[0058] A virucidal composition may comprise a concentrated composition that can be diluted to form a composition for use or a ready-to-use (RTU) composition. A solid virucidal composition provides a solution for use, which is a dilutable liquid concentrate, which can be further diluted to form a composition for use or an RTU composition. Beneficially, the composition overcomes the limitations of the prior art in that it can provide a dilutable concentrate. Generally, a concentrate refers to a composition intended to provide a solution for use that is diluted with water to come into contact with an object, and to provide the desired cleaning, antimicrobial efficacy, etc. Antimicrobial and virucidal compositions that come into contact with an article may be called a concentrate or a composition for use (or solution for use), depending on the formulation used in the method herein. It should be understood that the concentrations of additional functional components in the composition, such as acids, anionic surfactants, and nonionic surfactants, will differ depending on whether the composition is provided as a concentrate or as a solution for use. Those skilled in the art can adjust the weight % of the composition to arrive at compositions with different dilution ratios, which are within the range of the disclosed compositions. Beneficially, within the range of active substances, the composition may be formulated to comprise a liquid or solid composition that is nearly or completely free of water.

[0059] The solution of use can be prepared from the concentrate by diluting the solid or liquid concentrate with water at a dilution ratio that provides a solution of use having the desired antiviral properties. The water used to dilute the concentrate and form the composition of use may be called diluent water or diluent and may vary depending on the context. Typical dilution ratios are about 1 to about 10,000. In one embodiment, the solid or liquid concentrate is diluted at a ratio of about 1:10 to about 1:10,000 solid or liquid concentrate to water, about 1:10 to about 1:1,000 solid or liquid concentrate to water, or about 1:10 to about 1:510 solid or liquid concentrate to water.

[0060] In another embodiment, the concentrate can be diluted in proportions of about 1 / 8 ounce / gallon to about 12 ounces / gallon, about 1 / 4 ounce / gallon to about 1 ounce / gallon, or about 1 / 2 ounce / gallon to about 1 ounce / gallon, while providing disinfectant efficacy.

[0061] In another embodiment, the concentrate can be diluted in proportions of about 1 / 8 ounce / gallon to about 12 ounces / gallon, about 1 / 2 ounce / gallon to about 6 ounces / gallon, or about 1 ounce / gallon to about 4 ounces / gallon, while providing viricidal efficacy.

[0062] In another embodiment, the concentrate can be diluted in proportions of about 1 / 8 ounce / gallon to about 12 ounces / gallon, about 1 / 2 ounce / gallon to about 6 ounces / gallon, or about 1 ounce / gallon to about 4 ounces / gallon, while providing bactericidal efficacy.

[0063] In one embodiment, the diluted solution is prepared from a dilution of about 0.5% to about 3% by weight of the liquid concentrated composition.

[0064] In one embodiment, the concentrated liquid composition contains about 20% to about 60% anionic surfactant, preferably about 20% to about 40% anionic surfactant. In one embodiment, the liquid composition provides up to about 6000 ppm of anionic surfactant, or about 10 ppm to about 6000 ppm of anionic surfactant.

[0065] In one embodiment, the dilutable concentrated composition provides a working solution pH of about 1.5 to about 4, about 2 to about 4, about 2.0 to about 3.5, or about 2.0 to about 2.8, including the ranges between these.

[0066] Liquid compositions can be provided in various forms well understood by those skilled in the art. Compositions can also be manufactured to include saturated antimicrobial wipes, such as a paper or cloth substrate saturated with the liquid composition. In some embodiments, the liquid composition is provided as a liquid concentrate. In other embodiments, the liquid composition is provided as a ready-to-use liquid, such as a ready-to-use spray. Such ready-to-use applications provide an anionic surfactant in a concentration of about 10 ppm to about 6000 ppm. Such embodiments may further include additional functional components, such as solvents and defoamers. The addition of such components provides the desired viscoelasticity of the composition, enabling spraying, pumping, or the desired distribution. In some embodiments, it may be desirable to distribute a ready-to-use application having effervescence suitable for application to a vertical surface. Such effervescent applications may include ready-to-use formulations (e.g., effervescent triggers for distribution) or dilutable concentrates.

[0067] Solid compositions can be provided in various forms well understood by those skilled in the art. Compositions can be manufactured to include solid blocks, including those produced by pressing, extrusion, casting, tableting, etc. Solids can also include granules and powders, including fluid powders. In certain embodiments, solids can also include applicable packaging materials (e.g., films such as PVA film). Beneficially, solid compositions containing combinations of acids and anionic surfactants provide effective and stable solid alternatives to solids extruded using quaternary ammonium compounds. For example, in addition to solid blocks containing packs, tablets, powders, granules, etc., solids of various forms and sizes can be included. Various techniques can be used to form solids, including, for example, the use of fluidized beds and / or agglomeration to form solids from liquids.

[0068] Solid compositions may take the form of a solid as well as a size. In exemplary embodiments, solids may have weights of about 50 grams to about 250 grams, about 100 grams or more, and about 1 to about 10 kilograms. In certain embodiments, solid compositions may include unit doses, such as tablets or packs. A unit dose refers to a solid composition unit of a size such that the entire unit is used in a single use. When a solid composition is provided as a unit dose, it is typically provided as a cast solid, extruded pellet, or tablet having a size of about 1 gram to about 50 grams. In other embodiments, solid compositions are provided in the form of multi-use solids, such as blocks or multiple pellets, which can be repeatedly used to produce aqueous compositions for multiple applications or cleaning cycles. In certain embodiments, solid compositions are provided as pressed solids, cast solids, extruded blocks, or tablets having a mass of about 5 grams to about 10 kilograms. In certain embodiments, the multi-use form of a solid composition has a mass of about 1 kilogram to about 10 kilograms.

[0069] The hardness of solid cast and / or pressed solid compositions can range from the hardness of relatively dense and hard fused solid products, such as concrete, to the hardness characterized as a cured paste. In addition, the term “solid” refers to the state of the composition under the expected storage and use conditions of the solid cleaning composition. Generally, a composition is expected to remain in a solid form when exposed to temperatures up to approximately 100°F, up to approximately 120°F, or up to approximately 125°F, while maintaining physical and dimensional stability. The dimensional stability of a solid composition is confirmed by a growth index of less than approximately 3% when heated at temperatures up to approximately 100°F (40°C), up to approximately 120°F (50°C), or up to approximately 140°F (60°C) for at least 30 minutes or at least 1 hour, for extended periods such as up to 2 weeks, up to 4 weeks, up to 6 weeks, or up to 8 weeks, at humidity of approximately 40–65%.

[0070] acid The composition comprises at least one acid, which may include a strong acid or a weak acid. In embodiments, the composition comprises two acids. In such embodiments of the acid combination, the acids may be a combination of a weak acid and a strong acid. In other embodiments of the acid combination, the acids may be a combination of two weak acids or two strong acids. For the purposes of the present invention, the acid is a component that can be added to an aqueous system and results in a pH of less than 7. A strong acid that can be used is an acid that substantially dissociates an aqueous solution. "Weak" organic and inorganic acids are acids or acid components in which the initial dissociation step of protons from the acidic moiety is not essentially completed when the acid is dissolved in water at ambient temperature at a concentration within a range useful for forming the present composition.

[0071] While we do not wish to be constrained by theory, the acids in the composition help protonate the lipid envelope and / or capsid of the virus, reducing the tendency of the membrane to be electronically repelled by the anionic surfactant contained in the antiviral composition. Furthermore, the acids disclosed herein promote the generation of low pH buffers on the surface of the substrate, thereby extending the residual antimicrobial and antiviral activity of the compositions and products in which they are incorporated.

[0072] Examples of strong acids suitable for use in compositions include methanesulfonic acid, sulfuric acid, sodium bisulfate, phosphoric acid, phosphonic acid, nitric acid, sulfamic acid, hydrochloric acid, trichloroacetic acid, trifluoroacetic acid, toluenesulfonic acid, glutamic acid, etc.; and alkanesulfonic acids such as methanesulfonic acid, ethanesulfonic acid, linear alkylbenzenesulfonic acid, xylenesulfonic acid, cumenesulfonic acid, etc. In a preferred embodiment, to provide useful acidic compositions having a pH of less than about 4, preferably less than about 3, the composition contains a strong acid having a pKa of less than about 2.5. In one embodiment, the composition contains a strong acid in combination with an anionic surfactant, and optionally contains a weak acid.

[0073] Alpha-hydroxycarboxylic acids such as lactic acid, citric acid, tartaric acid, malic acid, and gluconic acid; carboxylic acids such as formic acid, acetic acid, and propionic acid; ascorbic acid , Exemplary weak acids suitable for use in compositions, including other common organic acids such as bric acid, can also be used. In a preferred embodiment, to provide useful acidic compositions for use with a pH of less than about 4, preferably less than about 3, the composition contains a weak acid having a pKa greater than about 2.5. In one embodiment, the composition contains a weak acid in combination with an anionic surfactant and optionally a strong acid.

[0074] In certain embodiments, a combination of a strong acid and a weak acid dramatically improves antimicrobial and antiviral efficiency. In preferred embodiments, the acids include lactic acid and methanesulfonic acid. While not bound by a specific mechanism of action, it may be desirable to have a buffered acidic composition. For example, if the surface to be treated is not sufficiently clean, a combination of a weak acid and a strong acid may provide a buffered composition that can advantageously assist in the inactivation of pH-sensitive organisms.

[0075] In one embodiment, the composition comprises at least one acid in about 10% to about 80% by weight, at least one acid in about 20% to about 80% by weight, at least one acid in about 30% to about 70% by weight, or at least one acid in about 40% to about 70% by weight. In such embodiments, the acids may be strong acids and / or weak acids. In addition, all enumerated ranges include numbers defining the ranges, without limitation according to the present invention, and each integer within the defined range.

[0076] In certain embodiments, the composition comprises about 0.1% to about 30% by weight of a strong acid, about 1% to about 30% by weight of a strong acid, about 1% to about 25% by weight of a strong acid, about 5% to about 25% by weight of a strong acid, or about 5% to about 20% by weight of a strong acid.

[0077] In certain embodiments, the composition comprises about 1% to about 50% by weight of a weak acid, about 10% to about 50% by weight of a weak acid, about 15% to about 50% by weight of a weak acid, about 20% to about 50% by weight of a weak acid, or about 20% to about 45% by weight of a weak acid.

[0078] In certain embodiments, the composition, in combination with a weak acid, comprises a strong acid in an amount of about 0.1% to about 30% by weight, a strong acid in an amount of about 1% to about 30% by weight, a strong acid in an amount of about 1% to about 25% by weight, a strong acid in an amount of about 5% to about 25% by weight, or a strong acid in an amount of about 5% to about 20% by weight, and the composition comprises a weak acid in an amount of about 1% to about 50% by weight, a weak acid in an amount of about 10% to about 50% by weight, a weak acid in an amount of about 15% to about 50% by weight, a weak acid in an amount of about 20% to about 50% by weight, or a weak acid in an amount of about 20% to about 45% by weight. In addition, all listed ranges include numbers that define the range, without being limited in accordance with the present invention, and each integer within the defined range.

[0079] Anionic sulfonate surfactants The composition comprises at least one anionic sulfonate surfactant. In some embodiments, the composition comprises a combination of two anionic sulfonate surfactants. Anionic surfactants are surfactants classified by the negative charge of their hydrophobic components, or surfactants (e.g., carboxylic acids) in which the hydrophobic portion of the molecule is uncharged unless the pH rises above neutral. Carboxylates, sulfonates, sulfates, and phosphates are polar (hydrophilic) solubilizing groups found in anionic surfactants. Of the cations (counterions) associated with these polar groups, sodium, lithium, and potassium confer water solubility, ammonium and substituted ammonium ions provide both water and oil solubility, and calcium, barium, and magnesium promote oil solubility.

[0080] In another embodiment, the anionic sulfonate surfactant is alkyl sulfonates, including linear and branched primary and secondary alkyl sulfonates, as well as aromatic sulfonates with or without substituents. In one embodiment, the anionic sulfonate surfactant is an alpha-olefin sulfonate or a salt thereof. Alpha-olefin sulfonates are available as aqueous solutions, powders, or solid anhydrides. Preferred anionic sulfonates include C8-C22 alpha-olefin sulfonates or C8-C16 alpha-olefin sulfonates.

[0081] In another embodiment, the anionic sulfonate surfactant is a combination of alpha-olefin sulfonate or a salt thereof and an alkane sulfonate, preferably sodium alkane sulfonate.

[0082] Beneficial in this regard, alpha-olefin sulfonate surfactants are stable in hard water. They form clear, stable solutions, making them particularly attractive for consumer use. In comparison, other anionic surfactants such as LAS are unstable in hard water, forming unstable, cloudy solutions and / or precipitating from the solution.

[0083] In some embodiments, a combination of an anionic sulfonate surfactant and an additional anionic surfactant, preferably a powdered anionic surfactant, is used for solid compositions.

[0084] In one embodiment, the composition comprises about 0.1% to about 50% by weight of an alphaolefin sulfonate anionic surfactant, about 1% to about 50% by weight of an alphaolefin sulfonate anionic surfactant, about 10% to about 50% by weight of an alphaolefin sulfonate anionic surfactant, about 15% to about 50% by weight of an alphaolefin sulfonate anionic surfactant, about 20% to about 50% by weight of an alphaolefin sulfonate anionic surfactant, about 20% to about 45% by weight of an alphaolefin sulfonate anionic surfactant, or about 25% to about 40% by weight of an alphaolefin sulfonate anionic surfactant. In a preferred embodiment, the solid composition comprises about 1% to about 50% by weight of an alpha-olefin sulfonate anionic surfactant, about 10% to about 50% by weight of an alpha-olefin sulfonate anionic surfactant, about 15% to about 50% by weight of an alpha-olefin sulfonate anionic surfactant, about 20% to about 50% by weight of an alpha-olefin sulfonate anionic surfactant, about 20% to about 45% by weight of an alpha-olefin sulfonate anionic surfactant, or about 25% to about 40% by weight of an alpha-olefin sulfonate anionic surfactant. In addition, all listed ranges include numbers defining the range, without limitation according to the present invention, and each integer within the defined range.

[0085] Additional anionic surfactants In some embodiments, the composition comprises two or more anionic surfactants. In embodiments, the composition comprises an anionic alpha-olefin sulfonate and additional anionic surfactants such as sulfonated carboxylic acid esters, sulfates, carboxylates, or ethoxycarboxylates.

[0086] Exemplary additional anionic sulfonates include sulfonated carboxylic acid esters. In one embodiment, preferred alkyl sulfonate surfactants include C8-C22 alkyl sulfonates, or preferably C8-C16 alkyl sulfonates or C10-C22 alkyl sulfonates. In an exemplary embodiment, the anionic alkyl sulfonate surfactant is linear alkylbenzene sulfonic acid (LAS). The inclusion of additional anionic alkyl sulfonates may vary based on regulatory applicability for antiviral, disinfectant, and / or bactericidal applications.

[0087] Suitable anionic sulfate surfactants for use in compositions include alkyl ether sulfates, alkyl sulfates, linear and branched primary and secondary alkyl sulfates, alkyl ethoxy sulfates, fatty oleyl glycerol sulfates, alkylphenol ethylene oxide ether sulfates, and C5-C 17 Examples include acyl-N-(C1-C4 alkyl) and -N-(C1-C2 hydroxyalkyl) glucamine sulfates, as well as sulfates of alkyl polysaccharides such as alkyl polyglucosides. Also included are alkyl sulfates, alkyl poly(ethyleneoxy) ether sulfates, and aromatic poly(ethyleneoxy) sulfates, such as ethylene oxide and nonylphenol sulfates or concentrated products (typically containing 1-6 oxyethylene groups per molecule).

[0088] Suitable additional anionic surfactants for the composition include anionic carboxylate surfactants having a carboxylic acid or alpha-hydroxyl acid group. Suitable anionic carboxylate surfactants for use in the composition include carboxylic acids (and salts) such as alkanic acids (and alkanoates), ester carboxylic acids (including sulfonated carboxylic acid esters), ether carboxylic acids, and sulfonated fatty acids such as sulfonated oleic acid. In one embodiment, suitable ester carboxylic acids include alkyl succinates such as dioctyl sulfosuccinate. Such carboxylates include alkyl ethoxycarboxylates, alkylaryl ethoxycarboxylates, alkyl polyethoxypolycarboxylate surfactants, and soaps (e.g., alkylcarboxylates). Useful secondary carboxylates for the composition include those containing a carboxyl unit bonded to a secondary carbon. The secondary carbon may be in the ring structure, for example, as in p-octylbenzoic acid or as in alkyl-substituted cyclohexyl carboxylates. Secondary carboxylate surfactants typically do not contain ether bonds, ester bonds, or hydroxyl groups. Furthermore, they typically lack a nitrogen atom in the head group (amphiphilic moiety). Preferred secondary surfactants typically contain 11 to 13 total carbon atoms, but may have more carbon atoms (e.g., up to 16). Preferred carboxylates also include acyl amino acids (and salts) such as acyl glutamates, acyl peptides, sarcosinates (e.g., N-acyl sarcosinates), and taurates (e.g., fatty acid amides of N-acyl taurates and methyl taurides).

[0089] Suitable anionic surfactants include alkyl or alkylarylethoxycarboxylates of the following formulas: RO-(CH2CH2O) n (CH2) m -CO2X(3) In the formula, R is C8~C 22 It is an alkyl group, or [ka] R 1 is a C4 - C 16 alkyl group, n is an integer from 1 to 20, m is an integer from 1 to 3, and X is a counter ion such as hydrogen, sodium, potassium, lithium, ammonium, or an amine salt such as monoethanolamine, diethanolamine, or triethanolamine. In some embodiments, n is an integer from 4 to 10 and m is 1. In some embodiments, R is a C8 - C 16 alkyl group. In some embodiments, R is a C 12 -C 14 alkyl group, n is 4, and m is 1.

[0090] In other embodiments, R is

Chemical formula

[0091] Another class of anionic surfactants includes alpha - sulfonated carboxylic acid esters such as MC or PC - 48 from Stepan.

[0092] In one aspect, the composition includes from about 0 wt% to about 50 wt% of an additional anionic surfactant, from about 0 wt% to about 30 wt% of an additional anionic surfactant, from about 0.1 wt% to about 30 wt% of an additional anionic surfactant, or from about 1 wt% to about 30 wt% of an additional anionic surfactant. Additionally, all of the recited ranges are not limited according to the present invention, include the numbers defining the range, and include each integer within the defined range.

[0093] Additional functional components The components of the antiviral composition can be further combined with various additional functional components. In some embodiments, the antiviral composition comprising at least one acid and at least one anionic surfactant constitutes a large amount, or even substantially all, of the total weight of the composition. For example, in some embodiments, the additional functional components are present in little to no form.

[0094] In other embodiments, additional functional components may be included in the composition. Functional components impart desired properties and functionality to the composition. For the purposes of this application, the term “functional component” includes materials that, when dispersed or dissolved in a solution of use, such as an aqueous solution, and / or a concentrated solution, provide beneficial properties in a particular use. Some specific examples of functional materials are described in more detail below, but the specific materials described are merely examples, and a variety of other functional components may be used.

[0095] In preferred embodiments, the composition does not contain quaternary ammonium compounds. In additional embodiments, the composition does not contain conventional norovirus active substances, such as ethanol, silver citrate, and / or electrolytic chlorine. In additional embodiments, the composition does not contain alcohol and / or other organic solvents in order to beneficially provide a non-flammable product. In other embodiments, the composition may contain solidifying agents, defoaming agents, wetting agents, anti-redeposition agents, solubility modifiers, dispersants, rinsing aids, metal protectants, stabilizers, corrosion inhibitors, metal ion sequestering agents and / or chelating agents, threshold agents, fragrances and / or dyes, rheology modifiers or thickeners, hydrotropes or couplers, buffers, solvents, sensor indicators, and the like.

[0096] hydrogen peroxide In some embodiments, the composition comprises a hydrogen peroxide source (including hydrogen peroxide and / or a precursor). Solutions containing up to about 0.05–1.0 wt / wt% hydrogen peroxide are known to be effective for use as household and commercial disinfectants, bactericides, virucidates, sanitizers, and cleaning agents. Solutions containing about 3–4 wt / wt% hydrogen peroxide are suitable for use as multipurpose cleaning agents and bleach substitutes in medical facilities, homes, and commercial establishments. Solutions containing about 6–8 wt / wt% hydrogen peroxide are suitable for use as spore-cides, fungicides, virucidates, bactericides, broad-spectrum disinfectants, general-purpose cleaning agents, and bleach substitutes. Combinations of hydrogen peroxide with the compositions described herein offer further benefits for enhancing antiviral efficacy.

[0097] A hydrogen peroxide source, comprising an aqueous solution of hydrogen peroxide and / or a precursor, may be prepared as a concentrated aqueous solution. In some embodiments, a concentrated aqueous solution, e.g., hydrogen peroxide at up to 20 wt / wt%, is diluted when the concentrated composition is diluted. Alternatively, hydrogen peroxide may be prepared in a diluted form, e.g., 0.05 to 1.0 wt / wt%. In other embodiments, precursors of hydrogen peroxide may be used, comprising a perhydrate salt, including alkali metal salts such as perborate (usually monohydrate or tetrahydrate), percarbonate, persulfate, superphosphate, persilicate, and sodium salts of mixtures thereof. Examples of preferred precursors include perborate, percarbonate, and sodium salts of mixtures thereof. Without being limited to a specific mechanism of action, hydrogen peroxide provides further benefits to the compositions described herein to increase antibacterial and antiviral efficacy.

[0098] In some embodiments, the composition contains a hydrogen peroxide source in amounts of about 0% to about 50% by weight, about 0.1% to about 50% by weight, about 1% to about 40% by weight, and about 5% to about 40% by weight.

[0099] Solidifying agent A solidifying agent (also called a curing agent) may also be included in the solid composition. The solidifying agent may include an organic or inorganic compound or system of compounds that significantly contributes to the uniform solidification of the solid composition. When mixed and solidified during use to result in the uniform dissolution of the active substance from the solid composition, the solidifying agent must be able to form a homogeneous matrix with the active components of the solid composition.

[0100] An example of a solidifying agent is urea. Urea may be in the form of prillated beads or powder. Prillated urea is generally available from commercial sources, for example, Arcadian Sohio Company, Nitrogen Chemicals Division, as a mixture of particle sizes ranging from about 8 to 15 US mesh. The prillated form of urea is preferably ground to reduce the particle size to about 50 US mesh to about 125 US mesh, particularly about 75 to 100 US mesh, using a wet mill such as a single-screw or twin-screw extruder, Teledyne mixer, Ross emulsifier, etc.

[0101] The additional solidifying agent may be an organic curing agent, for example, a polyethylene glycol (PEG) compound. A preferred example is solid polyethylene glycol of the general formula H(OCH2CH2)nOH, where n is greater than 15, particularly about 30 to about 1700, and especially PEG4000, PEG1450, and PEG8000. Furthermore, PEG can include various molecular weights, for example, about 1,400 to about 30,000. In certain embodiments, the solidifying agent includes or is solid PEG, for example, PEG1500 to PEG20,000. In certain embodiments, PEG includes PEG1450, PEG3350, PEG4500, PEG8000, PEG20,000, and the like. A suitable solid polyethylene glycol is commercially available from Union Carbide under the trade name CARBOWAX.

[0102] Additional solidifying agents may include inorganic curing agents containing hydrateable inorganic salts, including but not limited to carbonates, sulfates, and bicarbonates, which may be alkali metal or alkaline earth metal salts. Suitable salts include lithium, sodium, potassium, calcium, magnesium, iron, strontium, zinc, manganese, lanthanum, titanium, gallium, aluminum, cobalt, copper, molybdenum, rhenium, rhodium, scandium, tin, and zirconium. Suitable metal salts include but not limited to sulfates, chlorides, phosphates, acetates, nitrates, and carbonates of sodium, lithium, and potassium. Particularly useful metal salts include sulfates, chlorides, and acetates of lithium, sodium, and potassium. The following patents disclose various combinations of solidifying agents, binders, and / or curing agents that can be used in the solid compositions of the present invention. The following U.S. patents are incorporated herein by reference in their entirety: U.S. Patent No. 7,153,820; No. 7,094,746; No. 7,087,569; No. 7,037,886; No. 6,831,054; No. 6,730,653; No. 6,660,707; No. 6,653,266; No. 6,583,094; No. 6,410,4 No. 95; No. 6,258,765; No. 6,177,392; No. 6,156,715; No. 5,858,299; No. 5,316,688; No. 5,234,615; No. 5,198,198; No. 5,078,301; No. 4,595,520; No. 4,680,134; No. RE32,763; and No. RE32818.

[0103] Furthermore, the solidifying agent may include polymers, and the thickeners may include natural gums such as xanthan gum, guar gum, or other gums from plant mucus; polysaccharide-based thickeners such as alginates, starches, and cellulosic polymers (e.g., carboxymethylcellulose); solid EO / PO block copolymers; polyacrylates; and hydrocolloids. In one embodiment, the thickener does not leave a contaminating residue on the surface of the object. For example, the thickener or gelling agent may be compatible with food or other sensitive products in the area of ​​contact.

[0104] The solidifying agent can be included in the composition in amounts ranging from approximately 0% to 70% by weight, 0% to 50% by weight, 0.01% to 30% by weight, approximately 0.01% to 20% by weight, or approximately 1% to 20% by weight.

[0105] surfactant In some embodiments, the composition includes additional surfactants. Suitable surfactants for use in the composition include, but are not limited to, nonionic surfactants, amphoteric surfactants, and / or zwitterionic surfactants. In some embodiments, the composition includes additional surfactants in amounts of about 0% to about 40% by weight, about 0.1% to about 38% by weight, about 1% to about 20% by weight, about 1% to about 15% by weight, or about 1% to about 6% by weight.

[0106] Nonionic surfactants Suitable nonionic surfactants for use with the compositions of the present invention include alkoxylated surfactants. Suitable alkoxylated surfactants include EO / PO copolymers, capped EO / PO copolymers, alcohol alkoxylates, capped alcohol alkoxylates, and mixtures thereof. Suitable alkoxylated surfactants for use as solvents include EO / PO block copolymers such as Pluronic and reverse Pluronic surfactants, alcohol alkoxylates such as Dehypon LS-54 (R-(EO)5(PO)4) and Dehypon LS-36 (R-(EO)3(PO)6), capped alcohol alkoxylates such as Plurafac LF221 and Tegoten EC11, and mixtures thereof.

[0107] In exemplary embodiments, a nonionic surfactant, available on the market under the trade name "Pluronic," is included in the composition as an additional surfactant. These compounds are formed by condensing ethylene oxide with a hydrophobic base formed by the condensation of propylene oxide and propylene glycol. The hydrophobic portion of this molecule has a molecular weight of approximately 1,500 to 1,800. The addition of polyoxyethylene radicals to this hydrophobic portion tends to increase the overall water solubility of the molecule, and the liquid properties of the product are maintained until the polyoxyethylene content is approximately 50% of the total weight of the condensation product.

[0108] Semipolar nonionic surfactants are another class of nonionic surfactants useful in the compositions of the present invention. Semipolar nonionic surfactants include amine oxides, phosphine oxides, sulfoxides, and their alkoxylated derivatives.

[0109] Amine oxides are tertiary amine oxides corresponding to the following general formula: [ka] It is a tertiary amine oxide corresponding to, where the arrow in the formula is the conventional representation of a semipolar bond, R 1 , R 2 , and R 3 R may be aliphatic, aromatic, heterocyclic, alicyclic, or a combination thereof. Generally, with respect to the amine oxide of the detergent in question, 1 R is an alkyl radical with approximately 8 to 24 carbon atoms. 2 and R 3 R is an alkyl or hydroxyalkyl group with 1 to 3 carbon atoms, or a mixture thereof. 2 and R 3 For example, they can be attached to each other through oxygen or nitrogen atoms to form a ring structure, R 4n is an alkylene or hydroxyalkylene group containing 2-3 carbon atoms, and n is in the range of 0 to about 20. Amine oxides can be produced from the corresponding amine and an oxidizing agent such as hydrogen peroxide.

[0110] Useful water-soluble amine oxide surfactants are selected from octyl, decyl, dodecyl, isododecyl, coconut, or tallow alkyl di-(lower alkyl) amine oxides, and specific examples include octyldimethylamine oxide, nonyldimethylamine oxide, decyldimethylamine oxide, undecyldimethylamine oxide, dodecyldimethylamine oxide, isododecyldimethylamine oxide, tridecyldimethylamine oxide, tetradecyldimethylamine oxide, pentadecyldimethylamine oxide, hexadecyldimethylamine oxide, heptadecyldimethylamine oxide, These are octadecyldimethylamine oxide, dodecyldipropylamine oxide, tetradecyldipropylamine oxide, hexadecyldipropylamine oxide, tetradecyldibutylamine oxide, octadecyldibutylamine oxide, bis(2-hydroxyethyl)dodecylamine oxide, bis(2-hydroxyethyl)-3-dodecoxy-1-hydroxypropylamine oxide, dimethyl-(2-hydroxydodecyl)amine oxide, 3,6,9-trioctadecyldimethylamine oxide, and 3-dodecoxy-2-hydroxypropyldi-(2-hydroxyethyl)amine oxide.

[0111] Amphoteric surfactants Amphoteric or amphoteric electrolyte surfactants contain both basic and acidic hydrophilic groups as well as organic hydrophobic groups. These ionic entities may be either anionic or cationic groups as described herein for other types of surfactants. Basic nitrogen and acidic carboxylate groups are typical functional groups employed as basic and acidic hydrophilic groups. In some surfactants, sulfonates, sulfates, phosphonates, or phosphates provide a negative charge.

[0112] Amphoteric surfactants can be broadly described as derivatives of aliphatic secondary and tertiary amines, where the aliphatic radical may be linear or branched, and one of the aliphatic substituents contains about 8 to 18 carbon atoms, and another contains an anionic water-soluble group, e.g., carboxy, sulfo, sulfato, phosphat, or phosphono. Amphoteric surfactants are known to those skilled in the art and are subdivided into two main classes, as described in the “Surfactant Encyclopedia” Cosmetics & Toiletries, Vol. 104(2) 69-71 (1989), which is incorporated herein by reference in its entirety. The first class includes acyl / dialkylethylenediamine derivatives (e.g., 2-alkylhydroxyethylimidazoline derivatives) and their salts. The second class includes N-alkyl amino acids and their salts. Some amphoteric surfactants may be conceivable to belong to both classes.

[0113] Amphoteric surfactants can be synthesized by methods known to those skilled in the art. For example, 2-alkylhydroxyethylimidazoline is synthesized by condensation and ring closure of a long-chain carboxylic acid (or derivative) with a dialkylethylenediamine. Commercial amphoteric surfactants are derivatized, for example, with chloroacetic acid or ethyl acetate, by subsequent hydrolysis and ring opening of the imidazoline ring by alkylation. During alkylation, one or two carboxyalkyl groups react to form a tertiary amine and an ether linkage, and different alkylating agents yield different tertiary amines.

[0114] The long-chain imidazole derivatives used in the present invention generally have the following general formula: [ka] In the formula, R is an acyclic hydrophobic group containing about 8 to 18 carbon atoms, and M is a cation, generally sodium, for neutralizing the charge of the anion. Commercially well-known amphoteric compounds derived from imidazolines that can be used in this composition include, for example, cocoamphopropionate, cocoamphocarboxy-propionate, cocoamphoglycinate, cocoamphocarboxy-glycinate, cocoamphopropyl-sulfonate, and cocoamphocarboxy-propionic acid. Amphocarboxylic acids can be produced from aliphatic imidazolines, where the dicarboxylic acid functional group of the amphodicarboxylic acid is diacetic acid and / or dipropionic acid.

[0115] In this specification, the carboxymethylated compounds (glycinates) described above are often referred to as betaines. Betaines are a special class of amphoteric compounds described below in the following section entitled Zwitterionic surfactants.

[0116] Long-chain N-alkyl amino acids are readily prepared by the reaction RNH2, where R is C8-C 18 These are fatty amines having linear or branched alkyl, halogenated carboxylic acids. Alkylation of the primary amino group of an amino acid yields secondary and tertiary amines. The alkyl substituent may have two or more amino groups providing multiple reactive nitrogen centers. The most commercially available N-alkylamine acids are alkyl derivatives of beta-alanine or beta-N(2-carboxyethyl)alanine. Examples of commercially available N-alkylamino acid amphoteric electrolytes with applications in the present invention include alkylbeta-aminodipropionates, RN(C2H4COOM)2 and RNHC2H4COOM. In one embodiment, R may be an acyclic hydrophobic group containing about 8 to about 18 carbon atoms, and M may be a cation for neutralizing the charge of the anion.

[0117] Suitable amphoteric surfactants include those derived from coconut products such as coconut oil or coconut fatty acids. Additional suitable coconut-derived surfactants include, as part of their structure, an ethylenediamine moiety, an alkanolamide moiety, an amino acid moiety, e.g., glycine, or a combination thereof, and an aliphatic substituent with about 8 to 18 (e.g., 12) carbon atoms. Such surfactants may also be considered alkylamphodicarboxylic acids. These amphoteric surfactants are C 12 -alkyl-C(O)-NH-CH2-CH2-N + (CH2-CH2-CO2Na)2-CH2-CH2-OH or C 12 -alkyl-C(O)-N(H)-CH2-CH2-N + It may include a chemical structure represented as (CH2-CO2Na)2-CH2-CH2-OH. Disodium cocoamphodipropionate is one preferred amphoteric surfactant, marketed by Rhodia Inc., Cranbury, NJ under the trade name Miranol® FBS. Another preferred coconut-derived amphoteric surfactant, having the chemical name disodium cocoampho diacetate, is also marketed by Rhodia Inc., Cranbury, NJ under the trade name Mirataine® JCHA.

[0118] A typical list of amphoteric classes and species of these surfactants is given in U.S. Patent No. 3,929,678, issued to Laughlin and Heuring on December 30, 1975. Further examples are given in “Surface Active Agents and Detergents” (Vol. I and II by Schwartz, Perry and Berch).

[0119] Zwitterionic surfactant Zwitterionic surfactants can be considered a subset of amphoteric surfactants and may contain anionic charges. Broadly speaking, zwitterionic surfactants can be described as derivatives of secondary and tertiary amines, derivatives of heterocyclic secondary and tertiary amines, or derivatives of quaternary ammonium, quaternary phosphonium, or tertiary sulfonium compounds. Typically, zwitterionic surfactants contain a positively charged quaternary ammonium, or optionally a sulfonium or phosphonium ion, a positively charged carboxyl group, and an alkyl group. Zwitterions generally contain cationic and anionic groups that ionize to roughly the same degree in the isoelectric region of the molecule, potentially leading to a strong "internal salt" attraction between the positive and negative charge centers. Examples of such zwitterionic synthetic surfactants include derivatives of aliphatic quaternary ammonium, phosphonium, and sulfonium compounds, in which the aliphatic radical may be linear or branched, one of the aliphatic substituents contains 8 to 18 carbon atoms, and the other contains an anionic water-soluble group, such as a carboxy, sulfonate, sulfate, phosphate, or phosphonate.

[0120] Betaine and sultaine surfactants are exemplary zwitterionic surfactants for use herein. The general formulas of these compounds are: [ka] And in the formula, R 1 Y contains an alkyl, alkenyl, or hydroxyalkyl radical of 8 to 18 carbon atoms having 0 to 10 ethylene oxide moieties and 0 to 1 glyceryl moiety, Y is selected from the group consisting of nitrogen, phosphorus, and sulfur atoms, and R 2 x is an alkyl or monohydroxyalkyl group containing 1 to 3 carbon atoms, x is 1 when Y is a sulfur atom, and 2 when Y is a nitrogen or phosphorus atom, and R 3Z is an alkylene or hydroxyalkylene or hydroxyalkylene with 1 to 4 carbon atoms, and Z is a radical selected from the group consisting of carboxylate, sulfonate, sulfate, phosphonate, and phosphate groups.

[0121] Examples of zwitterionic surfactants having the structures listed above include 4-[N,N-di(2-hydroxyethyl)-N-octadecylammonio]-butane-1-carboxylate, 5-[S-3-hydroxypropyl-S-hexadecylsulfonio]-3-hydroxypentane-1-sulfate, 3-[P,P-diethyl-P-3,6,9-trioxatetracosanphosphonio]-2-hydroxypropane-1-phosphate, 3-[N,N-dipropyl-N-3-dodecoxy-2-hydroxypropyl-ammonio]-propane-1-phosphonate, 3-(N,N-dimethyl-N-hexadecylammonio)-propane-1-sulfonate, and 3-(N,N-dimethyl-N This includes hexadecylammonio)-2-hydroxy-propane-1-sulfonate, 4-[N,N-di(2(2-hydroxyethyl)-N(2-hydroxydodecyl)ammonio]-butane-1-carboxylate, 3-[S-ethyl-S-(3-dodecoxy-2-hydroxypropyl)sulfonio]-propane-1-phosphate, 3-[P,P-dimethyl-P-dodecylphosphonio]-propane-1-phosphonate, and S[N,N-di(3-hydroxypropyl)-N-hexadecylammonio]-2-hydroxypentane-1-sulfate. The alkyl groups contained in the detergent surfactant may be linear or branched, and may be saturated or unsaturated.

[0122] Suitable zwitterionic surfactants for use in this composition include betaines having the following general structure. [ka]

[0123] These surfactant betaines typically do not exhibit strong cationic or anionic characteristics at extreme pH levels, nor do they show reduced water solubility within these isoelectric ranges. Unlike "external" quaternary ammonium salts, betaines are compatible with anionic substances. Examples of suitable betaines include coconut acylamidopropyl dimethyl betaine, hexadecyldimethyl betaine, and C 12-14 Acylamidopropyl betaine, C 8-14 Acylamidehexyldiethylbetaine, 4-C 14-16 Acylmethylamide diethylammonio-1-carboxybutane, C 16-18 Acylamide dimethyl betaine, C 12-16 Acylamidopentanediethylbetaine, and C 12-16 Contains acylmethylamide dimethyl betaine.

[0124] The sultaine useful in this invention is of formula (R(R 1 )2N + R 2 SO 3- The compound comprises a compound having a C6-C 18 It is a hydrocarbyl group, and each R 1 Typically, independently, R is a C1-C3 alkyl group, e.g., methyl. 2 This is a C1-C6 hydrocarbyl group, for example, a C1-C3 alkylene or hydroxyalkylene group.

[0125] A typical list of zwitterionic classes and species of these surfactants is given in U.S. Patent No. 3,929,678, published December 30, 1975, to Laughlin and Heuring. Further examples are given in “Surface Active Agents and Detergents” (Vol. I and II by Schwartz, Perry, and Berch). Each of these references is incorporated herein in its entirety.

[0126] In one embodiment, the composition of the present invention comprises betaine. For example, the composition may contain cocoamidopropyl betaine.

[0127] defoaming agent Defoaming agents can also be included in the composition. Generally, defoaming agents that can be used according to the present invention preferably include alcohol alkoxylates and EO / PO block copolymers. Other defoaming agents include polyalkylene glycol condensates and propyl glycols, including polypropyl glycol. In some embodiments, the composition may include a defoaming agent or defoaming agent of food grade quality, considering the application examples of this method. For this purpose, one of the more effective defoaming agents is silicone. Silicones such as dimethyl silicone, glycol polysiloxane, methylphenol polysiloxane, trialkyl or tetraalkylsilane, hydrophobic silica defoaming agents, and mixtures thereof can all be used for defoaming applications. These defoaming agents can be present in concentration ranges of about 0.01% to 20% by weight, 0.01% to 20% by weight, about 0.01% to 5% by weight, or about 0.01% to about 1% by weight.

[0128] How to use The virucidal compositions are particularly well suited for treating surfaces requiring antimicrobial efficacy, including, for example, virucidal efficacy. In a further embodiment, the virucidal compositions are even better suited for treating surfaces requiring virucidal efficacy against small non-enveloped viruses, large non-enveloped viruses, and / or any enveloped viruses, without the use of any quaternary ammonium compounds and / or sulfonated anionic surfactants subject to regulatory restrictions. In a particular embodiment, the virucidal compositions are particularly well suited for treating surfaces that need to be inactivated for small non-enveloped viruses. Methods for inactivating viral populations are provided, and these methods include methods for inactivating murine norovirus, which are encompassed by this disclosure.

[0129] A method of using an antimicrobial agent, including antiviral sterilization with inactivation of the virus, comprises a contact step in which the antiviral composition is applied to a surface that requires treatment. In one embodiment, the contact of the composition is with a surface contaminated with the virus. The contaminated surface may be cleaned and / or soiled beforehand. In a preferred embodiment, the method of use provides complete sterilization of norovirus. Beneficially, in one embodiment, a reduction of more than 99.9% in such a population (a reduction of the order of 3-log), a reduction of more than 99.99% in such a population (a reduction of the order of 4-log), or a reduction of more than 99.999% in a population of norovirus on a surface (a reduction of the order of 5-log) is achieved with a contact time of less than about 60 minutes, less than about 30 minutes, less than about 15 minutes, less than about 5 minutes, less than about 1 minute, less than about 30 seconds, or even less than about 15 seconds.

[0130] In a further embodiment, contact with the antiviral composition may be to hard surfaces that come into contact with food and / or do not come into contact with food. Such surfaces may further include instruments such as medical instruments. Surfaces may include various objects, including those cleaned by disinfection of a third sink. In a further embodiment, contact with the composition may be for CIP (clean-in-place) applications.

[0131] In further embodiments, contact of the composition may be with a cleaning machine for cleaning supplies, such as for cleaning supplies.

[0132] In further embodiments, the composition may be used for third-sink disinfection or first-sink sterilizing detergent applications. In yet another embodiment, the contact may be beneficially compatible with first-sink detergents, thereby allowing it to be used as a water recycling tool to combine the third-sink disinfection process with the first-sink detergent. This is an advantage over conventional compositions containing quaternary ammonium compounds that are not compatible with first-sink detergents.

[0133] In further embodiments, contact of the composition may be with a tissue surface, including in tissue processing applications. Exemplary tissue surfaces include, for example, mammalian skin, such as animal or human skin, including human hands.

[0134] The various surfaces to which the composition can be applied may include any conventional application methods. Application may include, for example, wiping, spraying, dipping, or immersion. Contact may also include providing a solid that is first dissolved in water to form a solution for contact. The contact step allows the composition to come into contact with the contaminated surface for a predetermined time. The amount of time may be sufficient to allow contact, including a few seconds to 1 hour, about 15 seconds, or about 30 seconds to about 60 minutes, or any range in between. In preferred embodiments, the contact time required for antiviral effectiveness is less than about 30 minutes, less than about 15 minutes, less than about 10 minutes, less than about 5 minutes, or less than 1 minute. In further embodiments, the contact time required for antiviral effectiveness is less than about 30 seconds, or even less than about 15 seconds. The method may include a single step of applying the composition onto the surface without direct physical removal, such as a rinsing step and / or a wiping step. Beneficially, in various embodiments, the composition can optionally provide a no-rinse application. As a further advantage, in various embodiments, the composition can optionally provide a wipe application. Furthermore, as a further advantage, in various embodiments, the composition can offer a no-rinse and no-wipe application.

[0135] In some embodiments, the solid composition includes a first step of diluting a concentrated liquid composition using a water source such as water (or forming an aqueous work composition from the solid) to form a work solution from the liquid concentrate or an aqueous work solution from the solid. The aqueous work solution can be further diluted to a desired work solution.

[0136] In some embodiments, the method may further include a pre-cleaning step, such that the cleaning composition is applied, wiped, and / or rinsed, followed by the application of the composition. The composition and its method of use may include treating a cleaned or soiled surface. In some embodiments, the amount of contact time between the composition and the surface is sufficient to reduce the population of microorganisms on the surface (including murine norovirus as a surrogate of norovirus) to provide a reduction of more than 99.9% (a reduction of the order of three-logs) in such populations, a reduction of more than 99.99% (a reduction of the order of four-logs) in such populations, or a reduction of more than 99.999% (a reduction of the order of five-logs) in the population of microorganisms and pathogens. The contact time is preferably less than about 30 minutes, less than about 15 minutes, or less than about 5 minutes.

[0137] The temperature conditions for the method may be in the range of approximately 40°F to 160°F, approximately 60°F to 140°F, or approximately 70°F to 140°F.

[0138] Beneficially, these methods do not require a rinsing step. In one embodiment, the composition is approved for contact with food and does not require a rinsing step. As a further advantage, this method does not cause corrosion and / or interfere with surfaces (e.g., cloudy, dull, or other negative aesthetic effects on the surface).

[0139] This method may optionally include the use of various sensors and / or indicators. In one embodiment, the level of the active ingredient in the solution of use can be monitored in various ways. In one approach, the critical pH of the solution at which the biocide activity of the product begins to decrease significantly is visually indicated by a color change, which is achieved by selecting a dye that exhibits a dramatic color change at this pH. The dye can be easily incorporated into the product, preferably incorporated into a polymer substrate to form a color-changing strip, which is placed in a container, for example, a third sink, and exhibits a color change when the solution passes the critical pH value. Additionally, the level of anionic surfactant in the solution of use can be monitored in a similar manner, and the color change will indicate the critical concentration of the anionic surfactant required for biocide activity.

[0140] In additional embodiments, as an alternative to visual indicators, properties of the solution in use, including pH, anionic activity, fluorescence, and / or conductivity, can be monitored by a sensor that provides a visual or audible signal when the solution falls out of a specified range. In some embodiments, a marker molecule can be added to the composition in which a change in the active ingredient in the solution in use induces a change in the physical and / or chemical properties of the marker molecule, and the change is quantified through signal processing.

[0141] In embodiments, the virucidal composition satisfies the sterilization requirements for EN1276 (bacterial suspension studies), EN13697 (bacterial carrier-based studies), and EN16615 (bacterial carrier-based studies) at 18°C ​​to 25°C, clean and / or contaminated conditions. In embodiments, the virucidal composition satisfies the virucidal requirements for EN14476 at 18°C ​​to 25°C, clean and / or contaminated conditions. As those skilled in the art will understand, a suspension study may also be referred to as a Phase 2, Step 1 (or 2.1-Suspension) study, and a carrier study may also be referred to as a Phase 2, Step 2 (or 2.2-Carrier) study or a laboratory-simulated surface test.

[0142] All publications and patent applications herein represent the ordinary level of art in the art to which the present invention relates. All publications and patent applications are incorporated herein by reference to the same extent that individual publications or patent applications are specifically and individually indicated to be incorporated by reference. [Examples]

[0143] Embodiments of the present invention are further defined in the following non-limiting examples. These examples illustrate specific embodiments of the present invention, but should be understood as being given only as examples. From the above description and these examples, those skilled in the art will be able to identify the essential features of the present invention and make various changes and modifications to the embodiments of the present invention without departing from the spirit and scope of the invention to suit various uses and conditions. Therefore, various modifications to the embodiments of the present invention, in addition to those shown and described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to be included within the scope of the appended claims.

[0144] The following abbreviations and / or trade names of the products used in the examples are described in more detail in Table 3 below: [Table 3]

[0145] For the test, EN hard water was prepared according to the following method: Solution A was prepared by dissolving 1.98 g of magnesium chloride (MgCl2) and 4.62 g of calcium chloride (CaCl2) in laboratory-purified water and diluting it to 100 mL. The solution was sterilized by membrane filtration. Solution B was prepared by dissolving 3.50 g of sodium bicarbonate (NaHCO3) in laboratory-purified water and diluting it to 100 mL. The solution was sterilized by membrane filtration. Both solutions were stored in a refrigerator (2-8°C) and used before the expiration date of each solution (1 month for solution A, 1 week for solution B). On the day of preparation, 6.0 mL of solution A and 8.0 mL of solution B were added to approximately 700 mL of sterile laboratory-purified water in a 1000 mL volumetric flask. Sterile laboratory-purified water was added to a volume of 1000 mL. The hard water was thoroughly mixed. The pH of the hard water was adjusted to the target pH range of 7.0 ± 0.2 with 1 N hydrochloric acid. Water hardness was determined by adding 10 mL of hard water to 40 mL of laboratory-grade purified water. A small amount of water hardness indicator and 1 mL of water hardness buffer were added and thoroughly mixed. The solution was then titrated for ppm as CaCO3 containing 0.01 M EDTA.

[0146] Example 1 Bactericidal efficacy screening. Bactericidal efficacy screening was performed with the chemicals listed in Table 4 according to EN1276, using both S. aureus ATCC 6538 with a 5-minute contact. Concentrated chemicals were prepared by adding the materials outlined in the table below to a glass beaker and stirring with a stirring rod until homogeneous. On the test day, a 1.25 wt% dilution of the test chemical was prepared and a 1 wt% dilution of the product was evaluated according to the table below, using EN hard water as the diluent (considering dilutions performed within the micro-efficacy method). pH was measured and recorded with a pH meter. Using a micropipette, MSA (70%) was added to the test sample in 10 μL increments until a pH of 2.0–2.1 was observed and MSA (70%) of the total volume was added, and the final pH of the solution used was recorded as shown in Tables 5–7.

[0147] The tests were conducted under clean conditions at 20°C with a 5-minute contact time using EN hard water (the treated panels had a contamination level of 0.3 g / L bovine serum albumin). The Crodasinic CS30 formulation could not be evaluated due to immediate instability of the composition. The tests were conducted over three different test days, with a "non-anionic control" and a "LAS control" included for each test day. [Table 4-1] [Table 4-2] [Table 5] [Table 6] [Table 7]

[0148] These results are shown in Table 8 and Figure 1. [Table 8]

[0149] Screening of various anionic chemicals shows that all anionic chemicals (excluding Akypo LF4 and negative controls) provide a reduction of 5-log or greater against S. aureus.

[0150] Example 2 Antiviral efficacy testing. Antiviral efficacy testing was performed using adenovirus and murine norovirus (MNV) with contact times of 5 minutes and 15 minutes using the chemicals listed in Table 9 (with some modifications to the formulations tested for antimicrobial efficacy) in EN14476. MNV is a type of norovirus used as a model for human norovirus. Concentrated chemicals were prepared by adding the materials outlined in the table below to a glass beaker and stirring with a stirring rod until homogeneous. On the test day, a 1.25 wt% dilution of the test chemical was prepared and a 1 wt% dilution of the product was evaluated according to the table below using EN hard water as the diluent (considering dilutions performed within the microefficacy method). pH was not measured for the antiviral test as the results were consistent with those of Example 1.

[0151] Each test had one replica for each test condition. The laboratory performed these tests at room temperature under clean conditions using EN hard water. The compositions were diluted to 1% by weight with a fixed active anionic concentration in a 1300 ppm working solution. [Table 9]

[0152] Cytotoxicity (log 10 CD50 / mL), titer of the viral control (log 10 TCID 50 / mL), viral titer after a certain period, and logarithmic decrease are shown in the results (see Figure). The results are shown in Figure 2 (adenovirus) and Figure 3 (MNV). The figures show the efficacy of the compositions evaluated with a 15-minute contact time. The adenovirus results (Figure 2) show that all anionic formulations provide ≥4 logarithmic killing at 15 minutes and "nd" (undetectable) viral measurements at 30 and 60 minutes. However, the MNV test (Figure 3) shows the unexpected result that only the AOS anionic formulation provides efficacy of ≥4 logarithmic killing at 15 minutes (and even earlier at 5 minutes).

[0153] This is a surprising result, as the tests were rerun to verify the accuracy of the tests. Additional tests were conducted over longer contact times, including 30 and 60 minutes, to determine whether the anionic surfactant provides virucidal efficacy against MNVs at longer contact times. The AOS-containing virucidal composition again outperformed the other anionic surfactants, confirming the unexpected result that the AOS-containing virucidal composition outperformed the other acid-containing anionic surfactants in providing virucidal efficacy.

[0154] Example 3 Additional antiviral efficacy testing. Following the unexpected results of Example 2, in which the AOS anionic formulation outperformed other anionic formulations against MNV, additional tests were conducted to evaluate the effects of dilution percentage and contact time. The method of Example 2 was followed, with modifications to the formulations shown in Table 10. The compositions were diluted to 1% by weight with a fixed active anionic concentration in a 1300 ppm solution used. [Table 10]

[0155] The results are shown in Figure 4. The figure again demonstrates the effectiveness of the AOS anionic composition at a 1% by weight dilution (providing an anionic concentration of 1300 ppm in the solution used), confirming the results of Example 2. In addition, the AOS anionic composition provides further antiviral efficacy at a 0.75% by weight dilution at 15 minutes, and at a further 0.5% by weight dilution at 30 minutes.

[0156] Although the present invention has been described in this manner, it will be apparent that this can vary in many ways. Such modifications should not be considered departures from the spirit and scope of the invention, and all such modifications are intended to be included within the following claims. The above specification provides a description of the manufacture and use of the disclosed compositions and methods. Since many embodiments can be made without departing from the spirit and scope of the invention, the present invention falls within the claims. Examples of embodiments of the present invention are listed in the following sections [1] to

[29] . [1] An acid comprising at least one acid, wherein the above acid includes a strong acid, a weak acid, or a combination thereof, At least one alpha-olefin sulfonate anionic surfactant, A virucidal composition comprising, The above composition is either a liquid or a solid. A composition having a usable pH of approximately 1.5 to approximately 4. [2] The composition according to item 1, wherein the alpha-olefin sulfonate is a C8-C22 alpha-olefin sulfonate. [3] The composition according to item 1, wherein the alpha-olefin sulfonate is a C8-C16 alpha-olefin sulfonate. [4] The composition according to any one of items 1 to 3, wherein the above acid comprises lactic acid and methanesulfonic acid. [5] A composition according to any one of items 1 to 4, further comprising a nonionic surfactant. [6] The composition according to item 1, further comprising an alkoxylated nonionic surfactant having an EO / PO block copolymer. [7] The composition according to any one of items 1 to 6, wherein the above acid constitutes about 10% to about 80% by weight, the above alpha-olefin sulfonate anionic surfactant constitutes about 0.1% to about 50% by weight, and further comprises about 1% to about 20% by weight of at least one additional functional component and / or about 1% to about 20% by weight of a nonionic surfactant. [8] The composition according to item 5 or 6, wherein the above acid constitutes about 10% to about 80% by weight, the above alpha-olefin sulfonate anionic surfactant constitutes about 0.1% to about 50% by weight, and the above nonionic surfactant constitutes about 1% to about 20% by weight. [9] (i) The weak acid constitutes about 10% to about 50% by weight, and the strong acid constitutes about 1% to about 30% by weight, (ii) the weak acid constitutes about 10% to about 50% by weight, or (iii) the strong acid constitutes about 1% to about 30% by weight, according to any one of items 1 to 6.

[10] The composition according to any one of items 1 to 8, wherein the composition is a liquid or a solid concentrate.

[11] The composition according to any one of items 1 to 10, further comprising an additional anionic surfactant.

[12] The composition according to item 11, wherein the additional anionic surfactant is a sulfonate, preferably an alkanesulfonate, preferably sodium alkanesulfonate.

[13] A method using a virucidal composition, wherein the above method is The virucidal composition described in any one of items 1 to 12 is brought into contact with the surface that requires treatment, A method comprising inactivating a viral population, wherein the antiviral inactivation is completed by reducing the viral population by at least three logarithms within approximately 60 minutes, 30 minutes, 10 minutes, 5 minutes, 1 minute, 30 seconds, or less than 15 seconds.

[14] The method according to item 13, wherein the above-mentioned antiviral composition is diluted in the solution of use before the above-mentioned contact step.

[15] The method according to item 14, wherein the diluted solution used is prepared from a dilution of approximately 0.5% to approximately 3% by weight.

[16] The method according to any one of items 13 to 15, wherein the above contact is by wiping, dipping, immersion, or spraying.

[17] The method according to any one of items 13 to 16, wherein the surface is a hard surface.

[18] The method according to item 17, wherein the hard surface is a hard surface that has been cleaned in advance, a surface contaminated with norovirus and / or other viral populations, and / or human or mammalian tissue.

[19] The method according to any one of items 13 to 18, wherein the above contact provides complete elimination of the above virus in less than one minute, and the aqueous use temperature of the above contact step is approximately 40°F to 160°F.

[20] The method according to item 13, wherein the above concentrate is diluted in a proportion of about 1 / 8 ounce / gallon to about 12 ounces / gallon to form a working solution of the above antiviral composition.

[21] The method according to any one of items 13 to 20, using sensors and / or indicators to measure and detect at least one of the following: the pH of the solution in which the composition loses its biocide efficacy, the concentration of the anionic surfactant in the solution used, fluorescence, and / or conductivity.

[22] The method according to any one of items 13 to 21, wherein the above-mentioned virus is a small non-enveloped virus, a large non-enveloped virus, and / or an enveloped virus.

[23] The method according to item 22, wherein the above-mentioned virus is human norovirus, adenovirus, and / or poliovirus.

[24] The method according to any one of items 13 to 23, wherein the inactivation of the above-mentioned virus population completes the inactivation by providing at least a 3-logarithmic reduction within approximately 10 minutes, 5 minutes, 1 minute, 30 seconds, or 15 seconds.

[25] The method according to any one of items 13 to 24, wherein the above-mentioned antiviral composition satisfies the requirements of EN1276 at 18°C ​​to 25°C under clean and / or contaminated conditions.

[26] The method according to any one of items 13 to 24, wherein the above-mentioned antiviral composition satisfies the requirements of EN13697 at 18°C ​​to 25°C under clean and / or contaminated conditions.

[27] The method according to any one of items 13 to 24, wherein the above-mentioned antiviral composition satisfies the requirements of EN16615 at 18°C ​​to 25°C under clean and / or contaminated conditions.

[28] The method according to any one of items 13 to 24, wherein the above-mentioned antiviral composition satisfies the requirements of EN14476 at 18°C ​​to 25°C under clean and / or contaminated conditions.

[29] The above method is the method described in any one of items 13 to 28, which does not require a rinsing step.

Claims

1. A combination of at least one strong acid and a weak acid in an amount of 10% by weight or more and less than 80% by weight, wherein the strong acid has a pKa of 2.5 or less, and 20% to 50% by weight of at least one alpha-olefin sulfonate anionic surfactant, Alkoxylated nonionic surfactant having an EO / PO block copolymer, A virucidal composition comprising, The composition is either a liquid or a solid. The pH of the composition used is 1.5 to 4. A composition wherein the weak acid contains lactic acid, and the strong acid contains methanesulfonic acid.

2. The composition according to claim 1, wherein the alpha-olefin sulfonate is a C8-C22 alpha-olefin sulfonate.

3. The composition according to claim 1, wherein the alpha-olefin sulfonate is a C8-C16 alpha-olefin sulfonate.

4. The composition according to any one of claims 1 to 3, wherein the strong acid constitutes 5% to 20% by weight, the nonionic surfactant constitutes 1% to 20% by weight, and further comprises at least one additional functional component in an amount of 1% to 20% by weight.

5. The composition according to any one of claims 1 to 3, wherein the strong acid constitutes 5% to 20% by weight, and the nonionic surfactant constitutes 1% to 20% by weight.

6. The composition according to any one of claims 1 to 5, wherein the weak acid constitutes 10% to 50% by weight.

7. The composition according to any one of claims 1 to 6, wherein the composition is a liquid or a solid concentrate.

8. The composition according to any one of claims 1 to 7, further comprising an additional anionic surfactant.

9. The composition according to claim 8, wherein the additional anionic surfactant is a sulfonate containing an alkane sulfonate.

10. A method using a virucidal composition, wherein the method is The antiviral composition according to any one of claims 1 to 9 is brought into contact with the surface that requires treatment, The method includes inactivating a virus population, wherein the inactivation is completed by reducing the virus population by at least three logarithms within 60 minutes, 30 minutes, 10 minutes, 5 minutes, 1 minute, 30 seconds, or less than 15 seconds. The method excludes human surfaces from the surface requiring the aforementioned treatment.

11. The method according to claim 10, wherein the antiviral composition is diluted in the solution of use before contact.

12. The method according to claim 11, wherein the diluted solution used is prepared from a dilution of 0.5% to 3% by weight.

13. The method according to any one of claims 10 to 12, wherein the contact is by wiping, dipping, immersion, or spraying.

14. The method according to any one of claims 10 to 13, wherein the surface is a hard surface.

15. The method according to claim 14, wherein the hard surface is a hard surface that has been cleaned in advance, or a surface contaminated with norovirus and / or other viral populations.

16. The method according to claim 11, wherein the contact provides complete elimination of the virus in less than one minute, and the contact is made at a water temperature of the solution used between 40°F and 160°F (4.4°C and 71.1°C).

17. The method according to claim 10, wherein the composition is a solid concentrate, and the solid concentrate is diluted in a proportion of 1 / 8 ounce / gallon to 12 ounces / gallon (1.0 g / L to 98.6 g / L) to form a working solution of the antiviral composition.

18. Using sensors and / or indicators, the following can be done: The pH of the solution in which the above composition loses its biocidal effect, The concentration of the anionic surfactant in the aforementioned solution, The fluorescence of the aforementioned solution used The conductivity of the aforementioned solution, or The method according to any one of claims 11, 12, 16, and 17, for measuring and detecting at least one of these combinations.

19. The method according to any one of claims 10 to 18, wherein the virus is a small non-enveloped virus, a large non-enveloped virus, and / or an enveloped virus.

20. The method according to claim 19, wherein the virus is human norovirus, adenovirus, and / or poliovirus.

21. The method according to any one of claims 10 to 20, wherein the inactivation of the virus population completes by providing at least a 3-logarithmic reduction within 10 minutes, 5 minutes, 1 minute, 30 seconds, or 15 seconds.

22. The method according to any one of claims 10 to 21, wherein the method does not require a rinsing step.

Images